Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Neurochemical and behavioral characterization of neuronal glutamate transporter EAAT3 heterozygous mice.

González LF, Henríquez-Belmar F, Delgado-Acevedo C, Cisternas-Olmedo M, Arriagada G, Sotomayor-Zárate R, Murphy DL, Moya PR.

Biol Res. 2017 Sep 19;50(1):29. doi: 10.1186/s40659-017-0138-3.

2.

Reduced Slc1a1 expression is associated with neuroinflammation and impaired sensorimotor gating and cognitive performance in mice: Implications for schizophrenia.

Afshari P, Yao WD, Middleton FA.

PLoS One. 2017 Sep 8;12(9):e0183854. doi: 10.1371/journal.pone.0183854. eCollection 2017.

3.

OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior.

Zike ID, Chohan MO, Kopelman JM, Krasnow EN, Flicker D, Nautiyal KM, Bubser M, Kellendonk C, Jones CK, Stanwood G, Tanaka KF, Moore H, Ahmari SE, Veenstra-VanderWeele J.

Proc Natl Acad Sci U S A. 2017 May 30;114(22):5719-5724. doi: 10.1073/pnas.1701736114. Epub 2017 May 15.

PMID:
28507136
4.

Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Zike I, Xu T, Hong N, Veenstra-VanderWeele J.

Neuroscience. 2017 Mar 14;345:256-273. doi: 10.1016/j.neuroscience.2016.09.012. Epub 2016 Sep 16. Review.

PMID:
27646291
5.

The importance of the excitatory amino acid transporter 3 (EAAT3).

Bjørn-Yoshimoto WE, Underhill SM.

Neurochem Int. 2016 Sep;98:4-18. doi: 10.1016/j.neuint.2016.05.007. Epub 2016 May 24. Review.

6.

Genetic variation in neuronal glutamate transport genes and associations with posttraumatic seizure.

Ritter AC, Kammerer CM, Brooks MM, Conley YP, Wagner AK.

Epilepsia. 2016 Jun;57(6):984-93. doi: 10.1111/epi.13397. Epub 2016 May 7.

7.

DNA Methylation at the Neonatal State and at the Time of Diagnosis: Preliminary Support for an Association with the Estrogen Receptor 1, Gamma-Aminobutyric Acid B Receptor 1, and Myelin Oligodendrocyte Glycoprotein in Female Adolescent Patients with OCD.

Nissen JB, Hansen CS, Starnawska A, Mattheisen M, Børglum AD, Buttenschøn HN, Hollegaard M.

Front Psychiatry. 2016 Mar 18;7:35. doi: 10.3389/fpsyt.2016.00035. eCollection 2016.

8.

LOWER POSTERIOR CINGULATE CORTEX GLUTATHIONE LEVELS IN OBSESSIVE-COMPULSIVE DISORDER.

Brennan BP, Jensen JE, Perriello C, Pope HG Jr, Jenike MA, Hudson JI, Rauch SL, Kaufman MJ.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Feb 1;1(2):116-124.

9.

NEUROBIOLOGICAL EVIDENCE SUPPORTING GLUTAMATE'S ROLE IN PEDIATRIC OBSESSIVE COMPULSIVE DISORDER.

MacMaster FP, Rosenberg DR.

Child Adolesc Psychopharmacol News. 2010 Dec;15(6):6-10. No abstract available.

10.

Using mice to model Obsessive Compulsive Disorder: From genes to circuits.

Ahmari SE.

Neuroscience. 2016 May 3;321:121-137. doi: 10.1016/j.neuroscience.2015.11.009. Epub 2015 Nov 10. Review.

11.

Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment.

Zink M.

Adv Med. 2014;2014:317980. doi: 10.1155/2014/317980. Epub 2014 Jun 11. Review.

12.

A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders.

Grados MA, Atkins EB, Kovacikova GI, McVicar E.

Psychol Res Behav Manag. 2015 Apr 28;8:115-31. doi: 10.2147/PRBM.S58601. eCollection 2015. Review.

13.

DISSECTING OCD CIRCUITS: FROM ANIMAL MODELS TO TARGETED TREATMENTS.

Ahmari SE, Dougherty DD.

Depress Anxiety. 2015 Aug;32(8):550-62. doi: 10.1002/da.22367. Epub 2015 May 7. Review.

14.

An association study between DLGAP1 rs11081062 and EFNA5 rs26728 polymorphisms with obsessive-compulsive disorder in a Chinese Han population.

Li J, Cui J, Wang X, Ma J, Niu H, Ma X, Zhang X, Liu S.

Neuropsychiatr Dis Treat. 2015 Apr 1;11:897-905. doi: 10.2147/NDT.S75009. eCollection 2015.

15.

Glutamate and the Treatment of Obsessive-Compulsive Disorder.

Macmaster FP, Rosenberg DR.

Psychopharm Rev. 2010 May 1;45(5):33-40. No abstract available.

16.

The Genetics of Obsessive-Compulsive Disorder.

Bloch MH, Pittenger C.

Curr Psychiatry Rev. 2010 May 1;6(2):91-103.

17.

Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.

Schirmbeck F, Zink M.

Front Pharmacol. 2013 Aug 9;4:99. doi: 10.3389/fphar.2013.00099. eCollection 2013.

18.

Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB.

Neuropsychopharmacology. 2013 Nov;38(12):2475-83. doi: 10.1038/npp.2013.150. Epub 2013 Jun 19.

19.

Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder.

Porton B, Greenberg BD, Askland K, Serra LM, Gesmonde J, Rudnick G, Rasmussen SA, Kao HT.

Transl Psychiatry. 2013 May 21;3:e259. doi: 10.1038/tp.2013.35.

20.

Long-term outcome in adults with obsessive-compulsive disorder.

Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros-Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C.

Depress Anxiety. 2013 Aug;30(8):716-22. doi: 10.1002/da.22103. Epub 2013 Mar 26.

Supplemental Content

Support Center